Business India ×
  Magazine:
Health

Published on: Nov. 17, 2020, 11:22 a.m.
Pfizer’s vaccine offers new hope
  • Pfizer said its mRNA vaccine has a 90 per cent effectiveness rate

By Business India Editorial

In a major relief to the pandemic-afflicted world, US pharma giant Pfizer announced last fortnight its Covid-19 vaccine was over 90 per cent effective in late-stage clinical trials. The news signalled a new hope for controlling the pandemic. In fact, US Health Secretary Alex Azar said if Pfizer Inc submits the positive initial data from its Covid-19 vaccine trial to health regulators as quickly as expected, the US government plans to begin vaccinating Americans in December. The mRNA (messenger Ribonucleic Acid) vaccine, developed with Germany’s BioNTech, targets spike proteins. Unlike a normal vaccine, RNA vaccines work by introducing an mRNA sequence (the molecule which tells cells what to build) which is coded for a disease-specific antigen. 

Instead of using weakened forms of the Covid-19 virus to trigger a lasting immune response, mRNA vaccines use only the virus’s genetic code. While these kinds of vaccines have been used in labs and animals, this is the first time it has been licensed for use in humans. And so, the efficacy data has a larger bearing. It proves mRNA vaccines actually work in humans. It also shows companies like Moderna who’ve also been banking on the mRNA revolution, might find success with their candidate vaccines as well.

Over a three-week period, researchers administered two vaccine doses to 43,538 volunteers; around half received the vaccine, the other half placebos. Across all participants, Pfizer logged 94 total Covid-19 cases, with a 90 per cent effectiveness rate for the vaccinated group. The trial is expected to continue until 164 people develop the disease. However, the interim results, based on the observation of 94 Covid-positive volunteers, indicate that most people who contracted the disease had received a placebo. Thereby indicating that those that received the vaccine developed some sort of immunity. Pfizer is suggesting that the vaccine might be 90 per cent effective.

US will get a lion’s share 

The US FDA needs follow-up data to make sure Pfizer’s vaccine isn’t harmful. The company hopes to have that ready as early as mid-November and could seek ‘emergency use’ approval from the FDA. Once it is approved, Pfizer says it can produce 50 million doses by the end of 2020 and 1.3 billion in 2021. However, each patient requires two doses, so half that number may actually receive it. Upon FDA authorisation, the United States would receive about 20 million doses of the Pfizer vaccine per month, Azar said, on a call with reporters. 

Pfizer and BioNTech refused to take money from the US government as they feared government intervention may delay their work. They believed they could initiate and wrap up vaccine trials much faster without government intervention. But the Trump dispensation promised to buy 100 million doses for $1.95 billion in the event their vaccine proved successful. So, a lion’s share of the early vaccines will go to US citizens. The US would need 375 million doses to cover 75 per cent of its adult population. It is believed that Pfizer had the efficacy data for a while now. Yet, the company chose not to disclose the results before the US elections. That ultimately led President Trump to dub Pfizer a coward as it didn’t announce the results prior to the elections. But the company denied that.

However, approval isn’t the only hurdle. Pfizer’s vaccine must be stored at -94°F, which could make it extremely difficult to deliver to many places. The cold storage requirements could impede Pfizer’s ability to reach rural healthcare systems and nursing homes, or less wealthy nations, which may not have the funds for the cold chain infrastructure. Moderna’s vaccine, widely viewed as the next-most-promising candidate, can be kept at -4°F. 

However, nearly 10.4 million coronavirus cases and over 241,000 fatalities have been reported since February and the US is desperately looking for a promising vaccine. Until then, President-elect Joe Biden has urged Americans to practise social distancing and wear masks.

If everything goes well, this could usher in a revolution in vaccine production the likes of which we’ve never seen before and Pfizer and BioNtech might gain emergency authorisation for their vaccine by the end of this year. Top US infectious disease expert, Anthony Fauci, also said in an interview with MSNBC that he expects the doses of the vaccine to be available for certain high priority groups in December.

On the flip side, the safety data isn’t out yet and the efficacy numbers haven’t been vetted by outside researchers. In fact, we will only have additional information by the end of November. Also, the current assessment is based on seven days of participant follow-ups. But eventually, as more days pass by, several additional participants in the study are bound to contract Covid-19 and Pfizer will have improved clarity on the long-term efficacy of its vaccine.

Don't miss this

Cover Feature

Fight against Covid-19: No time for complacency

A fresh surge of Covid-19 cases indicates that a second wave of the pandemic is imminent

Special Report

Has Covid broken the back of the economy?

Has the hard lockdown without required planning caught the economy in a vicious cycle?

Focus

Big business gets a second chance in banking

Can companies be 'fit and proper' to own banks again? The RBI thinks so

Corporate Report

STT GDC set to expand footprint

The company emerges as a dominant player in the Indian data center services market

Our letter to you, once a week.
Register with The CSR Weekly for free!

E-MAGAZINE
No time for complacency
Beyond the tipping point
IPL Big business
FROM THIS ISSUE

Automobiles

Editorial

Column

Corporate Houses

Government

Obituary

Social Responsibility

Women Empowerment

Tata Starbucks ties up with Educate Girls to empower women

Published on Dec. 2, 2020, 3:10 p.m.

The partnership aims to provide volunteering and educational support to those who have relocated to urban cities from villages

Environment

Indian Oil has a social initiative for a clean and green world

Published on Nov. 25, 2020, 2:53 a.m.

The public sector company is planting a tree for every retail customer visit during its TreeCheers campaign period

Education

MG Motor India launches Dakshata for students

Published on Nov. 17, 2020, 8:25 a.m.

The car company extends global tech expertise to students through the launch of ‘Dakshata’ in partnership with ASDC and Autobot India

Education

Shree Malani Group cushions the lives of the underprivileged

Published on Nov. 5, 2020, 10:44 a.m.

The Hyderabad-based foam and mattress maker gives laptops to under-graduate and post-graduate students

Climate Change

Energy

Smart Joules and energy saving solutions

Published on Nov. 17, 2020, 10:17 a.m.

The company's full-stack solution guarantees 15 per cent energy savings and zero upfront costs to the customer

Green Buildings

The GreenPro Ecolabel Standard for steel rebars will help a green built environment

Published on Nov. 5, 2020, 9:33 a.m.

Eight companies have already achieved CII’s Green Building Congress 2020 new standard

Land Use

Building resilience for an urbanising India

Published on Oct. 30, 2020, 10:25 a.m.

Climate change with its range of impact on regions and geographies needs the participation of communities

Green Buildings

How green is your storage? Ask CII-IGBC

Published on Oct. 30, 2020, 10:09 a.m.

The industry body’s new initiative will help logistics systems in India to save energy and water as well as improving health

Stay ahead of the times.
Register with The Climate Change Weekly for free!